upadacitinib oral atopic
Selected indexed studies
- Efficacy and Safety of Upadacitinib vs Dupilumab in Adults With Moderate-to-Severe Atopic Dermatitis: A Randomized Clinical Trial. (JAMA Dermatol, 2021) [PMID:34347860]
- Once-daily upadacitinib versus placebo in adolescents and adults with moderate-to-severe atopic dermatitis (Measure Up 1 and Measure Up 2): results from two replicate double-blind, randomised controlled phase 3 trials. (Lancet, 2021) [PMID:34023008]
- Systemic treatments for atopic dermatitis (eczema): Systematic review and network meta-analysis of randomized trials. (J Allergy Clin Immunol, 2023) [PMID:37678577]
_Worker-drafted node — pending editorial review._
Connections
upadacitinib oral atopic is a side effect of
Sources
- Safety Profile of Upadacitinib: Descriptive Analysis in Over 27,000 Patient-Years Across Rheumatoid Arthritis, Psoriatic Arthritis, Axial Spondyloarthritis, Atopic Dermatitis, and Inflammatory Bowel Disease. (2025) pubmed
- Efficacy and Safety of Upadacitinib vs Dupilumab in Adults With Moderate-to-Severe Atopic Dermatitis: A Randomized Clinical Trial. (2021) pubmed
- Systemic treatments for atopic dermatitis (eczema): Systematic review and network meta-analysis of randomized trials. (2023) pubmed
- JAK inhibitors in the treatment of atopic dermatitis. (2021) pubmed
- JAK-STAT signaling pathway in the pathogenesis of atopic dermatitis: An updated review. (2022) pubmed
- Treatment of atopic dermatitis: Recently approved drugs and advanced clinical development programs. (2024) pubmed
- Once-daily upadacitinib versus placebo in adolescents and adults with moderate-to-severe atopic dermatitis (Measure Up 1 and Measure Up 2): results from two replicate double-blind, randomised controlled phase 3 trials. (2021) pubmed
- Innovation in the treatment of atopic dermatitis: Emerging topical and oral Janus kinase inhibitors. (2022) pubmed
- Upadacitinib in adults with moderate to severe atopic dermatitis: 16-week results from a randomized, placebo-controlled trial. (2020) pubmed
- Efficacy and safety of switching from dupilumab to upadacitinib versus continuous upadacitinib in moderate-to-severe atopic dermatitis: Results from an open-label extension of the phase 3, randomized, controlled trial (Heads Up). (2023) pubmed